A prospective study evaluating the effectiveness of 18F-FAPI PET for the diagnosis of liver fibrosis: a comparison of liver biopsies

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054304

Enrollment

Unknown

Registered

2021-12-13

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis

Interventions

Gold Standard:Pathological confirmation by liver biopsy

Index test:18F-FAPI PET/CT

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed chronic liver disease, including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, non-alcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, congestive liver disease, etc.; 2. No liver disease other than liver tumor and liver fibrosis; 3. No history of malignant tumor; 4. Consent for FAPI PET and liver biopsy.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Anti-hepatic fibrosis treatment has been performed within half a year.

Design outcomes

Primary

Measure	Time frame
maximum standard intake;	—

Secondary

Measure	Time frame
novel PETCT examination (FAPI) uptake volume;	—

Countries

China

Contacts

Public ContactYang Guangjie

Affiliated Hospital of Qingdao University

ygj_2815@qq.com+86 17853297979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026